Aurinia Pharmaceuticals Reports Strong 2025 Results with 25% LUPKYNIS Sales Growth and Positive 2026 Guidance
Summary
Aurinia Pharmaceuticals announced strong financial results for 2025, featuring 25% growth in LUPKYNIS sales, a significant rise in profitability, and positive revenue guidance for 2026.
Key Events
-
Strong LUPKYNIS Sales Growth
Full-year 2025 LUPKYNIS net product sales increased 25% to $271.3 million, with Q4 sales up 29% to $74.2 million.
-
Significant Profitability Improvement
Full-year 2025 net income before income taxes rose 1443% to $114.2 million, contributing to diluted earnings per share of $2.07.
-
Positive 2026 Revenue Guidance
The company expects 2026 total revenue of $315 million to $325 million, representing 11% to 15% growth compared to 2025.
-
Substantial Operating Cash Flow
Cash flows from operating activities for 2025 increased 206% to $135.7 million, strengthening the company's financial position.
Analysis
Aurinia Pharmaceuticals delivered a robust financial performance for 2025, primarily driven by strong LUPKYNIS net product sales growth of 25% year-over-year. The company achieved a significant increase in net income before income taxes, demonstrating improved operational profitability. While the reported net income and diluted EPS were substantially boosted by a one-time income tax benefit from the release of a valuation allowance on deferred tax assets, the underlying business performance was strong. The positive 2026 revenue guidance, projecting 11% to 15% growth, indicates continued confidence in LUPKYNIS adoption and overall business trajectory. Additionally, the company's share repurchase program in 2025 signals a commitment to returning value to shareholders.
At the time of this filing, AUPH was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $6.55 to $16.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.